echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Single-cell RNA sequencing reveals the evolution of the immune response in GBM progression

    Single-cell RNA sequencing reveals the evolution of the immune response in GBM progression

    • Last Update: 2022-10-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com







    Alan Yeo et al.
    of Harvard Medical School in the United States used single-cell transcriptomics and flow cytometry to reveal large-scale comprehensive longitudinal changes
    in immune cell composition throughout tumor progression in a genetic mouse GBM model driven by epidermal growth factor receptors.

    The results were published online in the May 2022 issue of Nature Immunology
    .





    ——Excerpt from the article chapter


    【Ref: Yeo AT, et al.
    Nat Immunol.
    2022 Jun; 23(6):971-984.
    doi: 10.
    1038/s41590-022-01215-0.
    Epub 2022 May 27】


    Research background




    Glioblastoma (GBM) is an incurable primary malignant brain tumor characterized by a large number of immune components
    that promote tumor development.

    But little is known about changes in the GBM immune microenvironment during tumor progression
    .

    Alan Yeo et al.
    of Harvard Medical School in the United States used single-cell transcriptomics and flow cytology to reveal large-scale comprehensive longitudinal changes
    in immune cell composition throughout tumor progression in a genetic mouse GBM model driven by epidermal growth factor receptors (EGFR).

    The results were published online in the May 2022 issue of Nature Immunology
    .





    Research Methods



    To determine cell interactions in GBM progression, the authors used gene editing to create a GBM mouse model in which tumors are initiated
    by in situ deletion of human EGFR overexpression binding CDKN2A and PTEN.

    The authors performed uniform UMAP dimensionality reduction on 27633 CD45-cells and 36304 CD45+ cells, generating 17 and 20 subsets
    from CD45- and CD45+ samples, respectively.

    Four dendritic cell (DC) subsets, four macrophage subsets, and four T cell/natural killer (NK) cell subsets
    were detected.

    Subpopulation 3 are CD4 T cells (Cd4+); Subpopulation 7 consists of CD8 T cells (Cd8+) and NK cells (Gzma+); Subsets 3 and 32 contain regulatory T cells (Tregs, Cd4+ Il2ra+) as well as 3 microglia subsets
    .

    Subsets of 19S stage cells of early and late GBM mice were significantly increased with normal brain tissue controls; A 5-fold increase in EdU+ microglia in GBM mouse models (10.
    07±2.
    21%: 2.
    22±1.
    92%) demonstrated microglial proliferation
    in GBM tissues.

    EdU+ GBM microglia contain upregulated genes
    related to mitosis, cytoplasmic division, cell division and cell cycle.

    In the GBM tumor microenvironment (TME), microglia subsets respond
    to tumors through proliferation and less participation in polarization procedures.

    Through signaling pathway analysis, the authors found that one microglial subpopulation can respond to tumors by supporting pro-inflammatory procedures, while another microglial subset lacks this function
    .









    The authors then analyzed 32 cytokines and found that most (22/32) cytokines were enriched in CD45+ cells, indicating that most intratumor cytokines and their receptors were expressed more in the CD45+ cell population than in cancer cells
    .

    The authors also analyzed the expression of immune checkpoints in CD45+ cells and found that most checkpoint transcripts were expressed in CD45+ cells, mainly in T cells and bone marrow cells
    .



    By performing a temporal longitudinal evolution analysis of GBM, the authors found that EGFR+ cells are absent in normal brain tissue and increase
    significantly in early and late GBM.

    Early GBM is mainly composed of microglia, and late GBM shows increased
    macrophage infiltration.



    Results of the study



    The authors finally analyzed the effect
    of radiotherapy combined with standard therapy of temozolomide on the GBM immune microenvironment.

    The 2-week treatment of mice, followed by flow cytometry analysis, showed that both radiotherapy and combination therapy increased the number of GranzymeB+ CD8+ T cells and decreased the number of EGFR+ cancer cells and CD45+ cells
    .

    The results suggest that radiation therapy can induce cancer cell death, while increased accumulation of GranzymeB+ CD8+ T cells may be associated with radiation-induced new epitopes, which are the reasons for
    prolonged survival.


    Conclusion of the study



    In summary, the authors performed single-cell RNA sequencing studies on the immune and non-immune composition of mouse GBMs at single-cell resolution, and performed longitudinal analysis
    of cell populations during initiation and progression.

    The authors observed that the innate immune population underwent dramatic changes
    in the high infiltration of immunosuppressive macrophages and neutrophils from the early stages of GBM development to the GBM end-stage.






    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.